Chicago, IL - ASCO 2013 Annual Meeting: - Alfredo Falcone, MD, during "#3505 Alfredo Falcone, MD FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. " at the American Society for Clinical Oncology (ASCO) Annual Meeting here today, Saturday June 1, 2013. Over 30,000 physicians, researchers and healthcare professionals from over 100 countries are attending the meeting which is being held at the McCormick Convention center and features the latest cancer research in the areas of basic and clinical science. Photo by © ASCO/Brian Powers 2013 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org
Chicago, IL - ASCO 2013 Annual Meeting: - Volker Heinemann, MD, during "#LBA3506 Volker Heinemann, MD Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). " at the American Society for Clinical Oncology (ASCO) Annual Meeting here today, Saturday June 1, 2013. Over 30,000 physicians, researchers and healthcare professionals from over 100 countries are attending the meeting which is being held at the McCormick Convention center and features the latest cancer research in the areas of basic and clinical science. Photo by © ASCO/Brian Powers 2013 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org
